1. Home
  2. RARE vs CVCO Comparison

RARE vs CVCO Comparison

Compare RARE & CVCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RARE
  • CVCO
  • Stock Information
  • Founded
  • RARE 2010
  • CVCO 1965
  • Country
  • RARE United States
  • CVCO United States
  • Employees
  • RARE N/A
  • CVCO N/A
  • Industry
  • RARE Biotechnology: Pharmaceutical Preparations
  • CVCO Homebuilding
  • Sector
  • RARE Health Care
  • CVCO Consumer Discretionary
  • Exchange
  • RARE Nasdaq
  • CVCO Nasdaq
  • Market Cap
  • RARE 5.2B
  • CVCO 4.2B
  • IPO Year
  • RARE 2014
  • CVCO N/A
  • Fundamental
  • Price
  • RARE $43.98
  • CVCO $451.35
  • Analyst Decision
  • RARE Strong Buy
  • CVCO Buy
  • Analyst Count
  • RARE 14
  • CVCO 2
  • Target Price
  • RARE $88.43
  • CVCO $487.50
  • AVG Volume (30 Days)
  • RARE 717.6K
  • CVCO 68.0K
  • Earning Date
  • RARE 02-13-2025
  • CVCO 01-30-2025
  • Dividend Yield
  • RARE N/A
  • CVCO N/A
  • EPS Growth
  • RARE N/A
  • CVCO N/A
  • EPS
  • RARE N/A
  • CVCO 17.66
  • Revenue
  • RARE $522,745,000.00
  • CVCO $1,851,947,000.00
  • Revenue This Year
  • RARE $27.36
  • CVCO $10.04
  • Revenue Next Year
  • RARE $18.61
  • CVCO $7.24
  • P/E Ratio
  • RARE N/A
  • CVCO $25.78
  • Revenue Growth
  • RARE 27.44
  • CVCO N/A
  • 52 Week Low
  • RARE $37.02
  • CVCO $304.10
  • 52 Week High
  • RARE $60.37
  • CVCO $544.08
  • Technical
  • Relative Strength Index (RSI)
  • RARE 33.50
  • CVCO 35.07
  • Support Level
  • RARE $41.45
  • CVCO $438.90
  • Resistance Level
  • RARE $50.00
  • CVCO $506.99
  • Average True Range (ATR)
  • RARE 1.83
  • CVCO 12.19
  • MACD
  • RARE -0.31
  • CVCO -9.16
  • Stochastic Oscillator
  • RARE 26.55
  • CVCO 12.14

About RARE Ultragenyx Pharmaceutical Inc.

Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.

About CVCO Cavco Industries Inc. When Issued

Cavco Industries Inc designs and produces factory-built homes under the Cavco Homes, Fleetwood Homes, and Palm Harbor Homes brands. It also produces modular homes, park model homes, and vacation cabins, as well as commercial structures, among others. The company operates principally in two segments: Factory-built housing, which includes wholesale and retail systems-built housing operations, and the Financial services segment, which includes manufactured housing consumer finance and insurance. Cavco receives a majority of its revenue from the Factory-built housing segment.

Share on Social Networks: